Tasurgratinib

Eisai announced that it has obtained manufacturing and marketing approval for fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor ‘TASFYGO® Tablets 35mg’ (tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. In Japan, it has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW), and the marketing authorization application was submitted in December 2023. TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.